Annual General Meeting Announcement
argenx SE (Euronext & Nasdaq: ARGX), a leader in immunology, is inviting its shareholders to participate in the Annual General Meeting scheduled for 13:00 CET on a Tuesday in the not-so-distant future. The gathering will be held at the Hilton Amsterdam Schiphol. This meeting promises to be an insightful event for all stakeholders interested in the progress of the company and its innovative treatments aimed at severe autoimmune diseases.
Meeting Agenda Highlights
The agenda includes reviewing and adopting the annual accounts, an advisory vote regarding the recent remuneration report, and discharging the company directors for their 2024 performance. A significant proposal will also be put forth to reappoint Anthony Rosenberg to the Board of Directors while introducing a new remuneration policy that reflects the company’s commitment to growth and shareholder value.
Invitation and Participation
As a valued shareholder, your participation is highly encouraged. The formal notice detailing how to attend the meeting, including options for in-person or proxy attendance, as well as e-voting procedures, can be found on the argenx website. Shareholders are encouraged to consider exercising their voting rights to influence the management of the company effectively.
Annual Report Availability
The financial landscape and achievements of argenx are documented in the annual report, which is available for review on the company's website. This report offers insights into the company’s performance and strategic direction over the past year, demonstrating its unwavering commitment to enhancing the lives of patients battling autoimmune diseases worldwide.
About argenx
Dedicated to advancing immunology, argenx continues to lead the charge in developing effective therapies for those suffering from severe autoimmune conditions. The company collaborates with prestigious academic institutions through its Immunology Innovation Program, aiming to merge groundbreaking research with practical applications to bring novel antibody-based medicines to the market.
Innovative Therapeutics
The flagship product is a groundbreaking neonatal Fc receptor (FcRn) blocker, currently under evaluation for its potential across various serious autoimmune diseases. This endeavor emphasizes argenx's commitment to restoring health and hope through innovative medical solutions, backed by a robust pipeline of experimental therapies in various stages of development.
Shareholder Engagement
To foster better communication and engagement, argenx encourages shareholders to reach out for any inquiries regarding the meeting or other related matters. Stakeholders can connect via the contact details provided on the website, ensuring they remain informed and engaged with the company's ongoing journey.
Contact Information
For media inquiries, Ben Petok is available at Bpetok@argenx.com. Investors can reach out to Alexandra Roy at aroy@argenx.com, or Lynn Elton at lelton@argenx.com for inquiries pertaining to investment and financial strategies.
Frequently Asked Questions
What is the purpose of the argenx Annual General Meeting?
The meeting provides shareholders with insights into the company's performance and allows them to vote on important matters, including the adoption of annual accounts and remuneration reports.
How can shareholders attend the meeting?
Shareholders can attend the meeting in person or through proxy arrangements. Detailed instructions are available in the formal notice on the argenx website.
What can I expect to learn from the annual report?
The annual report provides an overview of financial performance and strategic initiatives undertaken by argenx, showcasing their advancements in immunology.
Who can shareholders contact for questions?
Shareholders can reach out to media liaison Ben Petok or investor relations representatives Alexandra Roy and Lynn Elton for assistance and inquiries.
What is the significance of the reappointment of Anthony Rosenberg?
Reappointing Anthony Rosenberg is crucial for the continuity of leadership on the Board of Directors, ensuring steady governance and direction for the company's future endeavors.
